TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 16
2 MARKET SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 GEOGRAPHICAL SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 DIAGNOSIS AND TREATMENT LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 MARKET END-USER COVERAGE GRID 27
2.11 VENDOR SHARE ANALYSIS 28
2.12 SECONDARY SOURCES 29
2.13 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 32
4.1 PESTEL'S MODEL 33
4.2 PORTER'S 5 FORCES 34
4.3 PIPELINE ANALYSIS 35
5 REGULATORY SCENARIO 36
6 MARKET OVERVIEW 38
6.1 DRIVERS 40
6.1.1 RISING PREVALENCE OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 40
6.1.2 INCREASING RESEARCH AND CLINICAL TRIALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 40
6.1.3 ADVANCEMENT IN GENE THERAPY 41
6.2 RESTRAINTS 42
6.2.1 STRINGENT REGULATORY APPROVALS FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 42
6.2.2 HIGH COST ASSOCIATED WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 43
6.3 OPPORTUNITIES 44
6.3.1 GOVERNMENT INITIATIVES FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS TREATMENT 44
6.3.2 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 45
6.4 CHALLENGES 46
6.4.1 COMPLEXITY IN DIAGNOSING HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 46
6.4.2 LIMITED PATIENT POOL FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 47
7 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET : BY COUNTRIES 48
8 MIDDLE EAST AND AFRICA HEREDITARY TRANSTHYRETIN AMYLOIDOSIS MARKET, COMPANY LANDSCAPE 81
8.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 81
9 SWOT ANALYSIS 82
10 COMPANY PROFILE 83
10.1 PFIZER INC. 83
10.1.1 COMPANY SNAPSHOT 83
10.1.2 REVENUE ANALYSIS 83
10.1.3 PRODUCT PORTFOLIO 84
10.1.4 RECENT DEVELOPMENT 84
10.2 GE HEALTHCARE.( A SUBSIDARY OF GENERAL ELECTRIC) 85
10.2.1 COMPANY SNAPSHOT 85
10.2.2 REVENUE ANALYSIS 85
10.2.3 PRODUCT PORTFOLIO 86
10.2.4 RECENT DEVELOPMENT 86
10.3 SIEMENS HEALTHCARE GMBH 87
10.3.1 COMPANY SNAPSHOT 87
10.3.2 REVENUE ANALYSIS 87
10.3.3 PRODUCT PORTFOLIO 88
10.3.4 RECENT DEVELOPMENT 88
10.4 KONINKLIJKE PHILIPS N.V. 89
10.4.1 COMPANY SNAPSHOT 89
10.4.2 REVENUE ANALYSIS 89
10.4.3 PRODUCT PORTFOLIO 90
10.4.4 RECENT DEVELOPMENT 90
10.5 CANON MEDICAL SYSTEMS CORPORATION 91
10.5.1 COMPANY SNAPSHOT 91
10.5.2 REVENUE ANALYSIS 91
10.5.3 PRODUCT PORTFOLIO 92
10.5.4 RECENT DEVELOPMENT 92
10.6 ALNYLAM PHARMACEUTICALS, INC. 93
10.6.1 COMPANY SNAPSHOT 93
10.6.2 REVENUE ANALYSIS 93
10.6.3 PRODUCT PORTFOLIO 94
10.6.4 RECENT DEVELOPMENT 94
10.7 ASTRAZENECA 95
10.7.1 COMPANY SNAPSHOT 95
10.7.2 REVENUE ANALYSIS 95
10.7.3 PRODUCT PORTFOLIO 96
10.7.4 RECENT DEVELOPMENT 96
10.8 FONAR CORP. 97
10.8.1 COMPANY SNAPSHOT 97
10.8.2 REVENUE ANALYSIS 97
10.8.3 PRODUCT PORTFOLIO 98
10.8.4 RECENT DEVELOPMENT 98
10.9 MINFOUND MEDICAL SYSTEMS CO., 99
10.9.1 COMPANY SNAPSHOT 99
10.9.2 PRODUCT PORTFOLIO 99
10.9.3 RECENT DEVELOPMENT 99
10.10 NEUSOFT CORPORATION 100
10.10.1 COMPANY SNAPSHOT 100
10.10.2 REVENUE ANALYSIS 100
10.10.3 PRODUCT PORTFOLIO 101
10.10.4 RECENT DEVELOPMENT 101
10.11 NIHON KOHDEN CORPORATION. 102
10.11.1 COMPANY SNAPSHOT 102
10.11.2 RECENT FINANCIALS 102
10.11.3 PRODUCT PORTFOLIO 103
10.11.4 RECENT DEVELOPMENT 103
10.12 NOVO NORDISK A/S 104
10.12.1 COMPANY SNAPSHOT 104
10.12.2 REVENUE ANALYSIS 104
10.12.3 PRODUCT PORTFOLIO 105
10.12.4 RECENT DEVELOPMENT 105
10.13 SCHILLER 106
10.13.1 COMPANY SNAPSHOT 106
10.13.2 PRODUCT PORTFOLIO 106
10.13.3 RECENT DEVELOPMENT 106
10.14 SHIMADZU CORPORATION 107
10.14.1 COMPANY SNAPSHOT 107
10.14.2 REVENUE ANALYSIS 107
10.14.3 PRODUCT PORTFOLIO 108
10.14.4 RECENT DEVELOPMENT 108
11 QUESTIONNAIRE 109
12 RELATED REPORTS 113

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.